First Command Advisory Services’s Arcutis Biotherapeutics ARQT Stock Holding History

First Command Advisory Services’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.4K	Hold	2,000	–	–	﹤0.01%	432
2026 Q1	$47.1K	Hold	2,000	–	–	﹤0.01%	363
2025 Q4	$58.1K	Hold	2,000	–	–	﹤0.01%	303
2025 Q3	$37.7K	Hold	2,000	–	–	﹤0.01%	332
2025 Q2	$28K	Hold	2,000	–	–	﹤0.01%	339
2025 Q1	$31.3K	Hold	2,000	–	–	﹤0.01%	312
2024 Q4	$27.9K	Hold	2,000	–	–	﹤0.01%	324
2024 Q3	$18.6K	Hold	2,000	–	–	﹤0.01%	349
2024 Q2	$18.6K	Hold	2,000	–	–	﹤0.01%	322
2024 Q1	$19.8K	Hold	2,000	–	–	﹤0.01%	317
2023 Q4	$6.46K	Buy	+2,000	New	+$5.44K	﹤0.01%	373

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Command Advisory Services's ARQT Position: Q2 2026 in Review

First Command Advisory Services held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 2,000 shares worth $52.4K. The position accounts for ﹤0.01% of the portfolio, ranked #432.

First Command Advisory Services first reported a position in ARQT in Q4 2023 and has held it in 11 quarters since. The position peaked at $58.1K in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

First Command Advisory Services held 2,000 shares of Arcutis Biotherapeutics worth $52.4K as of Q2 2026.
First Command Advisory Services left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up ﹤0.01% of First Command Advisory Services's portfolio in Q2 2026, its #432 holding.
First Command Advisory Services first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 11 quarters since.
First Command Advisory Services's Arcutis Biotherapeutics position peaked at $58.1K in Q4 2025.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on First Command Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.